2023-04-23
notable
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v2
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 674→confirmed 687
Study sitesdetails revised at 6 of 6 sites
2021-08-16
notable
Not Yet Recruiting→Recruiting Study Identification, Study Status, Study Description, Study Design, Arms and Interventions, Eligibility, Contacts/Locations, IPDSharing v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2020-12-31→confirmed 2021-04-01
Study sites0→6
InterventionsApatinib (Drug), Camrelizumab (Drug)→Camrelizumab (Drug), Rivoceranib (Apatinib) (Drug)
Eligibility criteria-94 characters
Inclusion Criteria:
Subjects with a clinical or histopathological diagnosis of HCC
Subjects who have underg [...] tematic treatment and locoregional therapy for HCC prior to surgical resection or ablationrandomization
Absence of major macrovascular invasion
No extrahepatic spread
Full recovery from surgicalCurative resection or ablation within 4 weeks prior to randomization [...] malignant tumor except HCC within 5 years or simultaneously
Recurrent HCC prior to randomization
Evidence of residual lesion, recurrentrecurrence, orand metastatic diseasemetastasis at randomization;
Moderate-to-severe ascites with [...] [...]
Study title+41 characters
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After SurgicalCurative Resection or Ablation